PERFLUTREN
Von-Hippel Lindau
UNC Lineberger Comprehensive Cancer CenterSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Von-Hippel Lindau cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Sonovue UNC Lineberger Comprehensive Cancer Center | Phase 2 | B |
Perflutren Lipid Microsphere Intravenous Suspension UNC Lineberger Comprehensive Cancer Center | Phase 2 | B |
Same molecule, other indications
PERFLUTREN is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →